Clinical Trial Update: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase I study to establish safety and maximum tolerated dose of autologous BCMA-targeting CAR T-cells in relapsed/refractory diffuse large B-cell lymphoma and m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Multiple Myeloma

Drugs mentioned

• Autologous BCMA-targeting CAR T-cells (BCMA-targeted autologous CAR T-cell therapy)

Snippet

Sponsor: Technische Universität Dresden | Conditions: Neoplasms, Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 | Status: RECRUITING